Table 1.
Characteristics of the patients.
Fig 1.
Representative images of immunohistochemical staining of NSCLC samples.
(A) Nestin, (B) ABCG2, (C) E-cadherin, and (D) Vimentin show positive expression. (original magnification, ×200).
Table 2.
Relationships between nestin expression and clinicopathological parameters.
Fig 2.
Representative cases of each EMT phenotype according to expression of E-cadherin and vimentin.
The cases are divided into the following 4 phenotypes; complete type, incomplete type1 (hybrid type), incomplete type2 (null type), and wild type (Lo, loss; Pr, preserve; P, positive; N, negative. original magnification, ×200).
Fig 3.
Cumulative survival of patients with NSCLC according to nestin expression estimated by the Kaplan-Meier method.
Panel (A) and (B) shows disease-free survival (DFS) and overall survival (OS), respectively. Nestin expression is significantly associated with poorer survival in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy, whereas there was no association between DFS and nestin expression.
Table 3.
Uni- and multivariable analyses of the effect of nestin expression on survival.